Brokerages expect that Aratana Therapeutics Inc (NASDAQ:PETX) will post ($0.33) earnings per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Aratana Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.29) and the lowest estimate coming in at ($0.38). Aratana Therapeutics posted earnings of ($0.52) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 36.5%. The business is scheduled to issue its next quarterly earnings results on Thursday, May 4th.
According to Zacks, analysts expect that Aratana Therapeutics will report full year earnings of ($1.29) per share for the current financial year, with EPS estimates ranging from ($1.57) to ($1.13). For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.69) per share, with EPS estimates ranging from ($1.14) to ($0.46). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that cover Aratana Therapeutics.
Aratana Therapeutics (NASDAQ:PETX) last issued its quarterly earnings data on Monday, March 13th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.42) by $0.22. The business had revenue of $0.29 million for the quarter, compared to the consensus estimate of $0.80 million. Aratana Therapeutics had a negative net margin of 60.32% and a negative return on equity of 19.87%. Aratana Therapeutics’s revenue was up 363.5% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.37) EPS.
A number of equities research analysts recently weighed in on PETX shares. Jefferies Group LLC dropped their price target on Aratana Therapeutics to $8.00 in a research note on Thursday, March 16th. Zacks Investment Research upgraded Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $8.50 price target on the stock in a research note on Wednesday, December 28th. Stifel Nicolaus cut Aratana Therapeutics from a “buy” rating to a “hold” rating and set a $8.00 price target on the stock. in a research note on Monday, February 6th. Finally, William Blair restated an “outperform” rating on shares of Aratana Therapeutics in a research note on Thursday, February 9th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $10.25.
In related news, insider Peter Steven St sold 50,000 shares of the stock in a transaction on Monday, April 17th. The stock was sold at an average price of $5.54, for a total value of $277,000.00. Following the sale, the insider now owns 582,693 shares in the company, valued at approximately $3,228,119.22. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 6.70% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Janus Capital Management LLC raised its position in shares of Aratana Therapeutics by 129.3% in the fourth quarter. Janus Capital Management LLC now owns 1,426,936 shares of the biopharmaceutical company’s stock worth $10,245,000 after buying an additional 804,753 shares in the last quarter. Broadfin Capital LLC raised its position in shares of Aratana Therapeutics by 19.7% in the fourth quarter. Broadfin Capital LLC now owns 3,695,442 shares of the biopharmaceutical company’s stock worth $26,533,000 after buying an additional 609,463 shares in the last quarter. DIAM Co. Ltd. purchased a new position in shares of Aratana Therapeutics during the third quarter worth approximately $747,000. Globeflex Capital L P purchased a new position in shares of Aratana Therapeutics during the third quarter worth approximately $595,000. Finally, Chicago Equity Partners LLC purchased a new position in shares of Aratana Therapeutics during the third quarter worth approximately $589,000. 75.44% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Aratana Therapeutics (NASDAQ:PETX) traded up 1.21% during trading on Thursday, reaching $5.87. 297,605 shares of the company traded hands. The stock’s market cap is $219.31 million. Aratana Therapeutics has a 12 month low of $4.97 and a 12 month high of $10.73. The stock’s 50 day moving average price is $5.66 and its 200-day moving average price is $7.24.
COPYRIGHT VIOLATION WARNING: “Brokerages Expect Aratana Therapeutics Inc (PETX) Will Post Earnings of -$0.33 Per Share” was posted by WKRB News and is the property of of WKRB News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at http://www.wkrb13.com/markets/2065720/brokerages-expect-aratana-therapeutics-inc-petx-will-post-earnings-of-0-33-per-share.html.
About Aratana Therapeutics
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by WKRB News (http://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://www.wkrb13.com/markets/2065720/brokerages-expect-aratana-therapeutics-inc-petx-will-post-earnings-of-0-33-per-share.html
Receive News & Ratings for Aratana Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.